637例地高辛血药浓度监测结果分析
|
摘要
目的:探讨临床药师在患者使用地高辛治疗的过程中进行药物治疗管理的效果,以促进地高辛的合理应用。方法:采用回顾性方法,对637例住院患者的地高辛血药浓度监测结果临床药师分析报告及临床诊治资料进行统计分析。结果:637例患者中,地高辛血药浓度<0.5 ng/ml的有107例(占16.80%),地高辛血药浓度为有效治疗血药浓度(0.5～2.0 ng/ml)的有349例(占54.79%),地高辛血药浓度>2.0 ng/ml的有181例(占28.41%);地高辛血药浓度受患者年龄、性别、肾功能及联合用药等因素的影响,临床药师对患者进行个体化药学服务,提高了疗效并降低了不良反应发生率。结论:临床药师在患者使用地高辛治疗的过程中积极开展个体化药学服务,促进了地高辛的合理应用,提高了药物治疗水平,保障了医疗安全。
OBJECTIVE: To explore the effects of clinical pharmacists in the management of drug therapy during the treatment of patients with digoxin, so as to promote the rational application of digoxin. METHODS: The analysis report of blood concentration monitoring results by clinical pharmacists, clinical diagnosis and treatment data of 637 inpatients with digoxin were analyzed retrospectively. RESULTS: Among the 637 patients, there were 107 cases(16.80%) with the blood concentration of digoxin <0.5 ng/ml, 349 cases(54.79%) with the blood concentration of digoxin as the effective treatment blood concentration(0.5-2.0 ng/ml), and 181 cases(28.41%) of digoxin blood concentration >2.0 ng/ml. The blood drug concentration of goxin was affected by patient's age, gender, renal function, drug combination and other factors. Clinical pharmacists provided individualized pharmaceutical services for patients, which improved the efficacy and reduced the incidence of adverse drug reactions. CONCLUSIONS: Clinical pharmacists actively carry out individualized pharmacy service during the treatment of patients with digoxin, promote the rational application of digoxin, improve the level of drug therapy, and ensure the medical safety.
OBJECTIVE: To explore the effects of clinical pharmacists in the management of drug therapy during the treatment of patients with digoxin, so as to promote the rational application of digoxin. METHODS: The analysis report of blood concentration monitoring results by clinical pharmacists, clinical diagnosis and treatment data of 637 inpatients with digoxin were analyzed retrospectively. RESULTS: Among the 637 patients, there were 107 cases(16.80%) with the blood concentration of digoxin <0.5 ng/ml, 349 cases(54.79%) with the blood concentration of digoxin as the effective treatment blood concentration(0.5-2.0 ng/ml), and 181 cases(28.41%) of digoxin blood concentration >2.0 ng/ml. The blood drug concentration of goxin was affected by patient's age, gender, renal function, drug combination and other factors. Clinical pharmacists provided individualized pharmaceutical services for patients, which improved the efficacy and reduced the incidence of adverse drug reactions. CONCLUSIONS: Clinical pharmacists actively carry out individualized pharmacy service during the treatment of patients with digoxin, promote the rational application of digoxin, improve the level of drug therapy, and ensure the medical safety.
引文
[1] Brunton LL,Chabner BA,Knollmann BC.古德曼·吉尔曼治疗学的药理学基础[M].12版.金有豫,李大魁,译.北京:人民卫生出版社,2016:609-610.
[2] 国家药典委员会.中华人民共和国药典·临床用药须知[S].2015年版.北京:中国医药科技出版社,2017:190-192.
[3] 郭健雄,李超,袁进,等.我院436例/次地高辛血药浓度监测结果分析[J].中国药房,2015,26(11):1499-1501.
[4] 高翔,肖绵娟,吴海燕.结合676例血药浓度监测结果探讨地高辛的合理应用[J].药品评价,2015,12(20):14-16,32.
[5] 王梓坤,陈舒晴,周颖,等.合并用药对有无肾损伤患者地高辛血药浓度影响因素分析[J].中国临床药理学与治疗学,2016,21(1):71-76.
[6] 刘泽辉,胡欣,张亚同,等.1996—2015年我院地高辛血药浓度监测情况及其影响因素分析[J].中国药房,2016,27(14):1921-1925.
[7] 赵海艳,冯婉玉,于泽,等.2015年某院治疗药物浓度监测结果回顾性分析[J].中国医院药学杂志,2017,37(15):1513-1516.
[8] 国家卫生计生委合理用药专家委员会,中国药师协会.心力衰竭合理用药指南[J].中国医学前沿杂志:电子版,2016,8(9):19-66.
[9] 林良沫,黄春新,韩方璇.冠心病患者地高辛中毒的药学监护[J].中国医院用药评价与分析,2016,16(5):694-696.
[10] 刘秀梅,贺含珍,张一,等.临床药师对心功能不全合并地高辛中毒患者的药学监护[J].中国医院用药评价与分析,2018,18(2):285-288.
[11] 李大魁,金有豫,汤光,等译.马丁代尔药物大典[M].37版.北京:化学工业出版社,2014:1215-1219.
[12] 都丽萍,李喜西,杜小莉,等.心力衰竭患者地高辛中毒的药物治疗管理[J].中国临床药理学杂志,2016,32(21):2000-2002.
[13] 高磊,肖建强,何国平.78例地高辛中毒的临床特点及相关因素分析[J].中国药业,2017,26(10):66-69.
[14] 王磊,沈纪中,葛卫红,等.基因多态性对地高辛代谢影响的研究进展[J].药学与临床研究,2014,22(1):72-76.
[15] 钱懿轶,王晶晶,王露婕,等.地高辛血药浓度监测的个体化药学服务实践与体会[J].中国医院药学杂志,2017,37(7):662-665.
[2] 国家药典委员会.中华人民共和国药典·临床用药须知[S].2015年版.北京:中国医药科技出版社,2017:190-192.
[3] 郭健雄,李超,袁进,等.我院436例/次地高辛血药浓度监测结果分析[J].中国药房,2015,26(11):1499-1501.
[4] 高翔,肖绵娟,吴海燕.结合676例血药浓度监测结果探讨地高辛的合理应用[J].药品评价,2015,12(20):14-16,32.
[5] 王梓坤,陈舒晴,周颖,等.合并用药对有无肾损伤患者地高辛血药浓度影响因素分析[J].中国临床药理学与治疗学,2016,21(1):71-76.
[6] 刘泽辉,胡欣,张亚同,等.1996—2015年我院地高辛血药浓度监测情况及其影响因素分析[J].中国药房,2016,27(14):1921-1925.
[7] 赵海艳,冯婉玉,于泽,等.2015年某院治疗药物浓度监测结果回顾性分析[J].中国医院药学杂志,2017,37(15):1513-1516.
[8] 国家卫生计生委合理用药专家委员会,中国药师协会.心力衰竭合理用药指南[J].中国医学前沿杂志:电子版,2016,8(9):19-66.
[9] 林良沫,黄春新,韩方璇.冠心病患者地高辛中毒的药学监护[J].中国医院用药评价与分析,2016,16(5):694-696.
[10] 刘秀梅,贺含珍,张一,等.临床药师对心功能不全合并地高辛中毒患者的药学监护[J].中国医院用药评价与分析,2018,18(2):285-288.
[11] 李大魁,金有豫,汤光,等译.马丁代尔药物大典[M].37版.北京:化学工业出版社,2014:1215-1219.
[12] 都丽萍,李喜西,杜小莉,等.心力衰竭患者地高辛中毒的药物治疗管理[J].中国临床药理学杂志,2016,32(21):2000-2002.
[13] 高磊,肖建强,何国平.78例地高辛中毒的临床特点及相关因素分析[J].中国药业,2017,26(10):66-69.
[14] 王磊,沈纪中,葛卫红,等.基因多态性对地高辛代谢影响的研究进展[J].药学与临床研究,2014,22(1):72-76.
[15] 钱懿轶,王晶晶,王露婕,等.地高辛血药浓度监测的个体化药学服务实践与体会[J].中国医院药学杂志,2017,37(7):662-665.